CVI Holdings’s Viking Therapeutics VKTX Stock Holding History

CVI Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,000	Closed	-$250K	–	299
2023 Q1	$250K	Buy	+15,000	New	+$155K	0.09%	133

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CVI Holdings's VKTX Position: Q2 2023 in Review

CVI Holdings sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 15,000 shares — an estimated $250K sold.

CVI Holdings first reported a position in VKTX in Q1 2023 and held it in 1 quarter. The position peaked at $250K in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

CVI Holdings reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
CVI Holdings sold 15,000 Viking Therapeutics shares in Q2 2023, an estimated $250K.
CVI Holdings first reported a position in Viking Therapeutics in Q1 2023 and held it in 1 quarter.
CVI Holdings's Viking Therapeutics position peaked at $250K in Q1 2023.
193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on CVI Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.